Theraclion Launches Its New Robotic Vein Platform SONOVEIN® HD
16 Mai 2022 - 7:00PM
Business Wire
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE),
an innovative company developing a scalable robotic platform for
non-invasive echotherapy, announces today the launch of
SONOVEIN® HD. This new system combines the first and only
extracorporeal therapeutic ultrasound solution with leading-edge
imaging capabilities from SuperSonic Imagine (recently acquired by
Hologic), made in Aix-en-Provence, France.
Less than 3 years after unveiling the first SONOVEIN®,
Theraclion is launching its CE-marked third-generation platform,
SONOVEIN® HD. This new edition is the result of Theraclion research
team’s technical developments and the integration of best-in-class
high-definition imaging technologies MACH30 10-12Mhz imaging
system.
“High-end visualization technology is key to an optimal
workflow, efficiency, and safety. The launch of SONOVEIN® HD is a
transforming event for Theraclion”, commented David Caumartin, CEO
of Theraclion.
“SONOVEIN® HD allowed me to complete the fastest vein treatment
I have ever done. It speeds up the process, avoiding repositioning
and increasing confidence. It truly is an innovation for vascular
doctors and will benefit patients,” explains Dr Guillaume
Stalnikiewicz, France, renowned vascular doctor and one of the
SONOVEIN global pioneers.
A few days after the treatment of the first patients in the US,
the SONOVEIN® HD release represents the ultimate technological
milestone in Theraclion’s ambition to revolutionize varicose vein
treatment. Theraclion is on track to transform this large global
market. Varicose veins affect an estimated 30% of the world’s adult
population and require about 5 million medical procedures
annually.
About Theraclion
At Theraclion we believe that surgery, as we know it, is
outdated. It converts optimistic patients into anxious individuals,
brilliant doctors into exhausted system executors and stretches
healthcare systems to the limit. We have disrupted this convention
by creating extracorporeal treatment platforms. We replace surgery
with a robotic treatment from outside the body using High Intensity
Focussed Ultrasound (HIFU). Our leading edge echotherapy platforms
are currently CE marked in non-invasive treatment of varicose veins
with SONOVEIN® and of breast fibroadenomas and thyroid nodules with
Echopulse®.
Located in Malakoff, near Paris, our employees live and breathe
innovation by extensive clinical research and harness artificial
intelligence. The market of varicose veins treatment alone requires
around 5 million procedures annually. It is a dynamic market in
which we change paradigms by making non-invasive echotherapy the
new standard.
For more information
Please visit www.theraclion.com and our patient website
www.echotherapy.com
Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220516005818/en/
Theraclion
David Auregan Chief Operating Officer
david.auregan@theraclion.com
Anja Kleber VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Apr 2023 bis Apr 2024